Method Of Co-culturing Cells Patents (Class 435/373)
-
Patent number: 8367409Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: GrantFiled: November 19, 2009Date of Patent: February 5, 2013Assignee: Anthrogenesis CorporationInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20130022582Abstract: The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.Type: ApplicationFiled: October 22, 2010Publication date: January 24, 2013Applicants: CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES, SERVICIO ANDALUZ DE SALUD, HOSPITAL CLINIC DE BARCELONAInventors: Simón Méndez Ferrer, Álvaro Urbano Ispizua
-
Patent number: 8357534Abstract: The invention concerns a human stem cell isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.Type: GrantFiled: February 6, 2008Date of Patent: January 22, 2013Assignee: University College Cardiff Consultants LimitedInventors: Charles William Archer, Samantha Nichola Haven, Gary Dowthwaite
-
Patent number: 8354277Abstract: An isolated primate embryonic cell is provided as well as cell cultures and cell lines derived therefrom. Also provided are methods of generating and using such cells.Type: GrantFiled: October 11, 2005Date of Patent: January 15, 2013Assignee: Technion Research & Development Foundation Ltd.Inventors: Michal Amit, Joseph Itskovitz-Eldor
-
Publication number: 20130005035Abstract: This disclosure describes methods for differentiating T cells and NK cells in vitro from hematopoietic stem cells or precursor cells. The technology is directed to methods for the production of selected populations of lymphocytes, such as T cells and NK cells. The availability of such cell populations allows for the complete reconstitution of a depleted, defective or missing lymphocyte population in a patient.Type: ApplicationFiled: December 2, 2010Publication date: January 3, 2013Inventors: Gerald John Spangrude, Birgitta H. Mitchell, Jared Manning
-
Patent number: 8343762Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from embryonic stem cells and embryoid bodies are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.Type: GrantFiled: January 11, 2007Date of Patent: January 1, 2013Assignee: Technion Research & Development Foundation Ltd.Inventors: Joseph Itskovitz-Eldor, Shahar Cohen
-
Publication number: 20120329125Abstract: Methods and systems for physically separating helper embryos from desired embryos in a group culturing technique in order to maintain the pedigree and genetic information of the desired embryos from different species, including cattle and human, and to provide the developmental benefits of group culturing. The separation of the groups of embryos can be the result of embedding one group of embryos in a gel or solid, or the groups can be physically separated by a membrane or other structure.Type: ApplicationFiled: June 24, 2011Publication date: December 27, 2012Applicant: INGURAN LLC.Inventors: Fuliang Du, Giorgio Antonio Presicce, Juan Moreno, Jie Xu, Shinn-Chin Wu
-
Publication number: 20120328638Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e.Type: ApplicationFiled: December 2, 2010Publication date: December 27, 2012Applicant: Onco Therapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 8338174Abstract: A material for ameliorating skin tissue provided by the invention comprises, as a main component, a culture obtained by culturing cells or tissue fragments derived from human or other mammalian alveolar mucosa. Typically, 50% or more of the cells contained in the culture are fibroblasts, and having a high growth rate and a high productivity in vascular endothelial cell growth factor (VEDF) and/or keratinocyte growth factor (KGF).Type: GrantFiled: June 24, 2009Date of Patent: December 25, 2012Assignee: National University Corporation Nagoya UniversityInventors: Katsumi Ebisawa, Ryuji Kato, Hideaki Kagami, Minoru Ueda
-
Patent number: 8338173Abstract: Cytotoxic ?? T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated ?? T cells to cross-present exogenous antigens to CD8+ ?? T cells, a process previously thought to be mediated best by dendritic cells. In particular, the present disclosure provides a method for cross-presentation of antigen derived from tumor cell or microbial organisms such as viruses, bacteria, yeasts, parasites, and the like, or from cells infected with such organisms, to a CD8+ ?? T cell. Still further, the present disclosure provides a method for treatment of a tumor or a chronic or recurrent infectious disease, comprising delivering an antigen-presenting autologous ?? T cell population above into a patient requiring such treatment. Still yet further, a method is described for preparing a peptide-specific effector T cell.Type: GrantFiled: November 14, 2008Date of Patent: December 25, 2012Assignee: University College Cardiff Consultants LimitedInventors: Bernhard Moser, Marlene Brandes Kuchen
-
Publication number: 20120322147Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.Type: ApplicationFiled: November 10, 2010Publication date: December 20, 2012Applicant: INSERM(institut National de la Sante et de la Recherche Medicale)Inventors: Philippe Mangeot, Vincent Lotteau
-
Publication number: 20120315700Abstract: Provided is a method of inducing tubulogenesis in normal endothelial cells comprising co-culturing the normal endothelial cells with tumor cells and forming tubules from the normal endothelial cells.Type: ApplicationFiled: August 15, 2012Publication date: December 13, 2012Applicant: BECTON, DICKINSON AND COMPANYInventor: MIN WU
-
Publication number: 20120315338Abstract: The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.Type: ApplicationFiled: December 3, 2010Publication date: December 13, 2012Applicant: Stem Cell & Regenerative Medicine International, Inc.Inventors: Feng Li, Shi-Jiang Lu
-
Patent number: 8329464Abstract: The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts (NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved.Type: GrantFiled: September 1, 2010Date of Patent: December 11, 2012Assignee: Kaohsiung Medical UniversityInventors: Wen-Cheng Chen, Chun-Cheng Hung, Chia-Ling Ko
-
Publication number: 20120309704Abstract: This description applies to pharmaceutical compositions comprising a mixture comprising one or more hERG1 channel blockers in combination with one or more compounds for anticancer therapy for use in the treatment of chemoresistant or potentially chemoresistant leukaemias and in vitro systems for the screening of substances suitable for use in the treatment of chemoresistant or potentially chemoresistant leukaemias.Type: ApplicationFiled: November 10, 2010Publication date: December 6, 2012Inventors: Annarosa Arcangeli, Andrea Becchetti, Serena Pillozzi, Marika Masselli, Emanuele De Lorenzo
-
Publication number: 20120309647Abstract: Cell co-culturing methods and arrays providing versatility and high resolution. A method comprising: providing at least one substrate; providing at least one first tip with at least one first cell-adhesion material disposed thereon, and at least one second tip with at least one second cell-adhesion material disposed thereon, wherein the first cell-adhesion material is different from the second cell-adhesion material; depositing the first cell-adhesion material from the first tip to the substrate to form at least one first deposit, and depositing the second cell-adhesion material from the second tip to the substrate to form at least one second deposit; and wherein the first and second deposits are capable of providing selective binding to at least one first cell so that the first cell selectively binds to the first deposit, and wherein the second deposit is capable of binding to at least one second cell.Type: ApplicationFiled: May 30, 2012Publication date: December 6, 2012Inventors: John M. Collins, Saju R. Nettikadan
-
Publication number: 20120308591Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.Type: ApplicationFiled: December 13, 2010Publication date: December 6, 2012Applicant: Onco Therapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 8318495Abstract: Genetically engineered hematopoietic progenitor cells that carry within them genes of interest, particularly for the expression of physiologically or pharmacologically active proteins. The hematopoietic progenitor cells are transduced in the presence of human mesenchymal stem cells which enhance transduction efficiency.Type: GrantFiled: May 28, 1999Date of Patent: November 27, 2012Assignee: Case Western Reserve UniversityInventor: Stanton L. Gerson
-
Patent number: 8318492Abstract: The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.Type: GrantFiled: February 25, 2008Date of Patent: November 27, 2012Assignee: Plasticell LimitedInventors: Yen Choo, Fraser Hornby, John Girdlestone
-
Patent number: 8318486Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.Type: GrantFiled: January 28, 2010Date of Patent: November 27, 2012Assignee: Technion Research & Development Foundation Ltd.Inventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 8309353Abstract: It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M.Type: GrantFiled: May 30, 2008Date of Patent: November 13, 2012Assignee: Kumamoto UniversityInventors: Shoen Kume, Nobuaki Shiraki, Kahoko Umeda, Kazuhiko Kume
-
Publication number: 20120269782Abstract: The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells.Type: ApplicationFiled: December 18, 2009Publication date: October 25, 2012Applicants: Sino-American United (Shanghai) Biotechnology Institute Co., Ltd., Sino-American iCELL (Shanghai) Biotechnology Co., Ltd.Inventors: Lihe Guo, Tianjin Liu
-
Patent number: 8293495Abstract: A method of creating a multicellular blood-brain barrier model is disclosed. In one embodiment, the method comprises culturing primary brain microvascular endothelial cells or embryonic stem cell-derived endothelial cells upon a permeable support in the presence of neural progenitor cells.Type: GrantFiled: August 25, 2011Date of Patent: October 23, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Eric V. Shusta, Christian Weidenfeller, Clive Niels Svendsen
-
Patent number: 8278101Abstract: A stem cell niche for expanding stem cells in culture is described. The stem cell niche includes a scaffold, a plurality of stromal mesenchymal stem cells, and a plurality of umbilical cord blood stem cells grown in a rotating culture chamber. One embodiment of the rotating culture chamber has a fluid-filled compartment in which the umbilical cord blood stem cells are grown in the presence of the mesenchymal stem cells seeded on the scaffold. The culture chamber has a dual flow valving member at each end, wherein a first flow path passes under a molecular cut-off membrane covering a central core that transverses the culture chamber and a second flow path flows through the culture chamber and allows cells to be harvested while in suspension.Type: GrantFiled: December 3, 2010Date of Patent: October 2, 2012Assignee: Synthecon, Inc.Inventor: Stephen S. Navran, Jr.
-
Publication number: 20120244617Abstract: Described is a scaffold that is strong enough to resist forces that exist inside a body, while possessing biocompatible surfaces. The scaffold is formed of a layer of mesh (e.g., Stainless Steel or Nitinol) that is tightly enclosed by a multi-layer biological matrix. The biological matrix can include three layers, such a first layer (smooth muscle cells) formed directly on the metal mesh, a second layer (fibroblast/myofibroblast cells) formed on the first layer, and a third layer (endothelial cells) formed on the second layer. The scaffold can be formed to operate as a variety of tissues, such as a heart valve or a vascular graft. For example, the mesh and corresponding biological matrix can be formed as leaflets, such that the scaffold is operable as a tissue heart valve.Type: ApplicationFiled: March 22, 2012Publication date: September 27, 2012Applicant: The Regents of the University of CaliforniaInventors: Seyedhamed Alavi, Arash Kheradvar
-
Patent number: 8273571Abstract: Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.Type: GrantFiled: May 27, 2011Date of Patent: September 25, 2012Assignee: Advanced Cell Technology, Inc.Inventors: James M. Robl, Jose Cibelli, Amy Burnside
-
Patent number: 8268620Abstract: Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.Type: GrantFiled: October 23, 2009Date of Patent: September 18, 2012Assignee: Wisconsin Alumni Research FoundationInventors: James Thomson, Junying Yu
-
Publication number: 20120231448Abstract: A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impurities C, D and E individually less than 0.5% and impurity F less than 2%, as measured by HPLC, is described. Uses of this high purity antibiotic hygromycin B include, for example, for in vitro cell selection.Type: ApplicationFiled: March 7, 2012Publication date: September 13, 2012Applicant: TOKU-E CompanyInventor: Qiubao PAN
-
Patent number: 8257973Abstract: The present invention relates to a method for co-culture of stem cells using feeder cells, more particularly to a method for culturing stem cells by using a membrane having a number of pores to separate stem cells and feeder cells. In the present invention, the culture condition of stem cells optimized is provided, in which stem cells and feeder cells are cultivated independently in separate spaces while permeating essential substances selectively. The stem cells prepared in the present invention continue to remain indifferent and be supported by feeder cells until needing being sub-cultured. In addition, the stem cells even for therapeutic use can be obtained without any contaminant since not pretreated with a cytostatic agent such as mitomycin or irradiated. Therefore, the method for co-culturing stem cells by using a membrane of the present invention can be widely used for clinical applications.Type: GrantFiled: May 29, 2007Date of Patent: September 4, 2012Assignee: Modern Cell & Tissue Technologies, Inc.Inventors: Hyun Sook Park, Sun Ray Lee
-
Patent number: 8257970Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumor cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: GrantFiled: September 17, 2007Date of Patent: September 4, 2012Assignee: UCL Biomodica PLCInventor: Mark Lowdell
-
Patent number: 8252583Abstract: A method for inducing differentiation of ES cells into cardiomyocytes, which comprises contacting the ES cells with an agonist for G-CSF receptor.Type: GrantFiled: June 6, 2008Date of Patent: August 28, 2012Assignee: Keiichi FukudaInventors: Keiichi Fukuda, Shinsuke Yuasa, Kenichiro Shimoji
-
Publication number: 20120208275Abstract: Methods are provided for obtaining expanded human cord blood cells or cord tissue cells expressing CD34. The methods involve seeding a sufficient amount of human cord blood cells or cord tissue cells with a sufficient amount of menstrual cells under co-culture conditions suitable to promote expansion of the cord cells, and co-culturing the cord cells with the menstrual cells under culture conditions that support at least two or more population doublings of the cord cells. Methods are also provided for growing expanded human cord cells to give rise to any one of colony forming units, colony forming unit granulocyte macrophages (CFU-GM), burst forming unit erythroids (BFU-E), and colony forming unit granulocyte erythrocyte macrophage megakaryocyte (CFU-GEMM) blood lineage precursor cells. The expanded cells may express CD34, SSEA-4, and HLA-II. Compositions of the expanded cells are also provided.Type: ApplicationFiled: August 12, 2011Publication date: August 16, 2012Applicant: Cryo-Cell International, Inc.Inventors: Mercedes A. Walton, Julie G. Allickson
-
Publication number: 20120202197Abstract: The present invention has successfully established a mixed culture system capable of actively proliferating a Kupffer cell in a primary culture of a cell population derived from a liver. Additionally, the present invention has successfully established a novel production method for efficiently producing a large amount of highly purified Kupffer cells using this mixed culture system.Type: ApplicationFiled: October 8, 2010Publication date: August 9, 2012Applicant: NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCESInventors: Hiroshi Kitani, Takato Takenouchi, Noriko Yamanaka, Miyako Yoshioka
-
Patent number: 8231868Abstract: Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated at a stage where the dendritic cells can inactivate T cell clones which would otherwise generate an undesired immune system response. The immature dendritic cells can be directly administered to the transplant recipient, or the dendritic cells can be co-incubated with the bone marrow or stem cell preparation, prior to transplantation, in order to suppress or eliminate anti-recipient donor T cells contaminating the bone marrow or stem cell preparation. The methods can be used to suppress graft versus host disease in recipients of transplanted bone marrow or stem cells, or to suppress rejection of transplanted organs or tissue.Type: GrantFiled: May 4, 2010Date of Patent: July 31, 2012Assignee: Yale UniversityInventors: Richard Leslie Edelson, Carole Berger, Michael Girardi
-
Publication number: 20120184009Abstract: A method and device for growing plant, animal or stem cells in a continuous manner.Type: ApplicationFiled: March 26, 2012Publication date: July 19, 2012Inventor: Eudes Francois Marie DE CRECY
-
Publication number: 20120183987Abstract: Disclosed herein are bioreactor systems and methods of utilizing said systems.Type: ApplicationFiled: June 18, 2010Publication date: July 19, 2012Inventors: Matthew R. Gevaert, David E. Orr
-
Publication number: 20120183985Abstract: Disclosed is a method for the manufacture of microtissues, comprising the steps of: providing a biomaterial substrate; simultaneously seeding a plurality of dermal papilla (DP) cells and keratinocytes on the substrate surface with a predetermined ratio and cellular density; co-culturing for a predetermined period; and carrying the keratinocytes to the substrate surface by the dermal papilla cells, aggregating and finally form a plurality of keratinocyte-dermal papilla cell microtissues, wherein the dermal papilla cells are located in a centre of the microtissue and the keratinocytes are sorted to a surface of the microtissue, and the keratinocytes are adult keratinocytes. The method can help to simply and economize the procedures for production of folliculoid microtissues with high-throughput. Once microtissues are transplanted to skin of subject, hair follicles can be regenerated.Type: ApplicationFiled: January 18, 2011Publication date: July 19, 2012Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Sung-Jan Lin, Chih-Chieh Chan, Chien-Mei Yen
-
Patent number: 8222033Abstract: The invention provides CD4+CD25? T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.Type: GrantFiled: July 11, 2003Date of Patent: July 17, 2012Assignee: Argos Therapeutics, Inc.Inventors: Gerold Schuler, Detlef Dieckmann
-
Patent number: 8222031Abstract: The present invention relates to methods for cultivating dermal fibroblasts, methods for preparing in vitro dermis equivalents, methods for preparing three-dimensional in vitro skin equivalents, an in vitro dermis equivalent, a three-dimensional in vitro skin equivalent, and methods for determining the effect of a chemical substance or of an agent on human skin cells using the in vitro dermis equivalent and/or the in vitro skin equivalent.Type: GrantFiled: June 15, 2009Date of Patent: July 17, 2012Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.Inventors: Michaela Noll, Thomas Graeve
-
Patent number: 8216779Abstract: Stable cell lines which produce the pathological form of PrP after infection with the infectious agent for CJD provide a high throughput assay to identify suitable treatment protocols and compositions. The stable cell lines also provide rich source of infectious CJD agent. They also may be used to identify vaccine candidates. Co-culture of neuronal cells with cells to be tested for infection with a TSE agent also provides a high throughput method for identifying infected cells.Type: GrantFiled: April 11, 2011Date of Patent: July 10, 2012Inventor: Laura Manuelidis
-
Publication number: 20120164163Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.Type: ApplicationFiled: May 25, 2010Publication date: June 28, 2012Inventors: Yasuharu Nishimura, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
-
Patent number: 8206980Abstract: A method for culture of hair follicular dermal sheath cells or precursor cells thereof which are potent cellular materials for such as hair regeneration by cell transplantation is provided. That is, by performing culture in an animal cell culture medium supplemented with platelet-derived growth factor AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), hair follicular dermal sheath cells are proliferated while sustaining their function, or hair follicular dermal sheath precursor cells are differentiated into dermal sheath cells and proliferated.Type: GrantFiled: October 2, 2006Date of Patent: June 26, 2012Assignees: Phoenixbio Co., Ltd., Biointegrence Inc.Inventors: Koei Toyoshima, Mikaru Matsunaga, Katsutoshi Yoshizato
-
Patent number: 8206979Abstract: The invention relates to a method for the expansion and differentiation of haematopoietic stem cells into enucleated erythrocytes, in two steps: a first step in a culture medium, where cell proliferation and erythmid differentiation are induced in the presence of growth factors, and a second step modeling a reconstitution of the microenvironment, substantially without erythropoietin (EPO). Optionally, the method of culture may comprise an intermediate step, with haematopoietic growth factors.Type: GrantFiled: March 11, 2005Date of Patent: June 26, 2012Assignee: Universite Pierre et Marie Curie — Paris VIInventors: Marie-Catherine Giarratana, Luc Douay
-
Publication number: 20120156231Abstract: The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.Type: ApplicationFiled: February 17, 2010Publication date: June 21, 2012Applicant: Oncotherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20120148544Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: January 12, 2012Publication date: June 14, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
-
Patent number: 8198083Abstract: An organotypic slice and a method of preparing an organotypic slice from a central nervous system tissue, wherein the organotypic slice comprises a brain slice obtained from a brain wherein mature synapses have not been established and the organotypic slice is seeded with a population of stem cells; wherein the organotypic slice has enhanced viability as compared to an organotypic slice comprising a similar brain slice not seeded with a population of stem cells.Type: GrantFiled: October 31, 2008Date of Patent: June 12, 2012Inventors: William Gunter Loudon, Shengwen Li, Brent A. Dethlefs
-
Patent number: 8198086Abstract: The present invention provides a method for arranging various cells as cell clusters in an arbitrary three-dimensional space and producing a three dimensional structure of a desired shape constituted exclusively by cells. Furthermore, the present invention provides a support provided with a substrate and a thread or needle-shaped material that penetrates the substrate and cell clusters for positioning cell clusters in arbitrary space. The support is provided with a sheet that can be removed as necessary for covering the substrate. Further, a method for using the support structure to position cell clusters in an arbitrary space and a method for the production of three-dimensional cell structures are provided.Type: GrantFiled: March 31, 2008Date of Patent: June 12, 2012Assignee: Kyushu University, National University CorporationInventors: Toshinobu Koga, Soichi Nagasato, Yukihide Iwamoto, Koichi Nakayama
-
Patent number: 8192732Abstract: This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.Type: GrantFiled: December 22, 2009Date of Patent: June 5, 2012Assignee: University of Central Florida Research Foundation, Inc.Inventors: Kiminobu Sugaya, Tingyu Qu, Ankur V. Vaghani, Christopher Brannen, Hojoong M. Kim, Jose S. Pulido, Xiajing Dong
-
Publication number: 20120135020Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: May 10, 2010Publication date: May 31, 2012Applicant: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Wantanabe
-
Publication number: 20120128705Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: March 31, 2010Publication date: May 24, 2012Applicant: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe